This HTML5 document contains 158 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n14http://linked.opendata.cz/resource/drugbank/drug/DB00455/identifier/pubchem-substance/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00455/identifier/kegg-drug/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00455/identifier/drugbank/
n11http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n27http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n6http://linked.opendata.cz/resource/drugbank/dosage/
n29http://linked.opendata.cz/resource/drugbank/mixture/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00455/identifier/national-drug-code-directory/
n9http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB00455/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n28http://www.rxlist.com/cgi/generic/
n24http://linked.opendata.cz/resource/drugbank/patent/
n30http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00455/identifier/wikipedia/
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n26http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n22http://www.drugs.com/cdi/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00455/identifier/pharmgkb/
n7http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00455/identifier/bindingdb/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00455/identifier/pubchem-compound/
n31http://linked.opendata.cz/resource/atc/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00455
rdf:type
n3:Drug
n3:description
Loratadine is a derivative of azatadine and a second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (histamine H1 antagonists) it lacks central nervous system depressing effects such as drowsiness. [PubChem]
n3:dosage
n6:271B543E-363D-11E5-9242-09173F13E4C5 n6:271B5441-363D-11E5-9242-09173F13E4C5 n6:271B5442-363D-11E5-9242-09173F13E4C5 n6:271B5443-363D-11E5-9242-09173F13E4C5 n6:271B543C-363D-11E5-9242-09173F13E4C5 n6:271B543D-363D-11E5-9242-09173F13E4C5 n6:271B543F-363D-11E5-9242-09173F13E4C5 n6:271B5440-363D-11E5-9242-09173F13E4C5 n6:271B543A-363D-11E5-9242-09173F13E4C5 n6:271B543B-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# See S: Desloratadine for allergic rhinitis. Am Fam Physician. 2003 Nov 15;68(10):2015-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14655812 # Menardo JL, Horak F, Danzig MR, Czarlewski W: A review of loratadine in the treatment of patients with allergic bronchial asthma. Clin Ther. 1997 Nov-Dec;19(6):1278-93; discussion 1523-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9444440 # Howarth PH: Histamine and asthma: an appraisal based on specific H1-receptor antagonism. Clin Exp Allergy. 1990 Aug;20 Suppl 2:31-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1977506 # Baroody FM, Naclerio RM: Antiallergic effects of H1-receptor antagonists. Allergy. 2000;55 Suppl 64:17-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11291777
n3:group
approved
n3:halfLife
8.4 hours
n3:indication
A self-medication that is used alone or in combination with pseudoephedrine sulfate for the symptomatic relief of seasonal allergic rhinitis. Also used for the symptomatic relief of pruritus, erythema, and urticaria associated with chronic idiopathic urticaria in patients (not for children under 6 unless directed by a clincian).
n3:manufacturer
n4:271B5412-363D-11E5-9242-09173F13E4C5 n4:271B5413-363D-11E5-9242-09173F13E4C5 n4:271B5410-363D-11E5-9242-09173F13E4C5 n4:271B5411-363D-11E5-9242-09173F13E4C5 n4:271B5416-363D-11E5-9242-09173F13E4C5 n4:271B5417-363D-11E5-9242-09173F13E4C5 n4:271B5414-363D-11E5-9242-09173F13E4C5 n4:271B5415-363D-11E5-9242-09173F13E4C5 n4:271B540A-363D-11E5-9242-09173F13E4C5 n4:271B540B-363D-11E5-9242-09173F13E4C5 n4:271B5408-363D-11E5-9242-09173F13E4C5 n4:271B5409-363D-11E5-9242-09173F13E4C5 n4:271B540E-363D-11E5-9242-09173F13E4C5 n4:271B540F-363D-11E5-9242-09173F13E4C5 n4:271B540C-363D-11E5-9242-09173F13E4C5 n4:271B540D-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00455 n30:DB00455
dcterms:title
Loratadine
adms:identifier
n13:3957 n14:46507853 n15:0378-1925-01 n16:PA450266 n17:22876 n18:D00364 n19:3820 n20:DB00455 n23:Loratadine
n3:mechanismOfAction
Loratadine competes with free histamine and exhibits specific, selective peripheral H<sub>1</sub> antagonistic activity. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine. Loratadine has low affinity for cholinergic receptors and does not exhibit any appreciable alpha-adrenergic blocking activity in-vitro. Loratadine also appears to suppress the release of histamine and leukotrienes from animal mast cells, and the release of leukotrienes from human lung fragments, although the clinical importance of this is unknown.
n3:packager
n4:271B53F1-363D-11E5-9242-09173F13E4C5 n4:271B53F2-363D-11E5-9242-09173F13E4C5 n4:271B53EF-363D-11E5-9242-09173F13E4C5 n4:271B53F0-363D-11E5-9242-09173F13E4C5 n4:271B53FD-363D-11E5-9242-09173F13E4C5 n4:271B53FE-363D-11E5-9242-09173F13E4C5 n4:271B53FB-363D-11E5-9242-09173F13E4C5 n4:271B53FC-363D-11E5-9242-09173F13E4C5 n4:271B53F9-363D-11E5-9242-09173F13E4C5 n4:271B53FA-363D-11E5-9242-09173F13E4C5 n4:271B53F7-363D-11E5-9242-09173F13E4C5 n4:271B53F8-363D-11E5-9242-09173F13E4C5 n4:271B5405-363D-11E5-9242-09173F13E4C5 n4:271B5403-363D-11E5-9242-09173F13E4C5 n4:271B5404-363D-11E5-9242-09173F13E4C5 n4:271B5401-363D-11E5-9242-09173F13E4C5 n4:271B5402-363D-11E5-9242-09173F13E4C5 n4:271B53FF-363D-11E5-9242-09173F13E4C5 n4:271B5400-363D-11E5-9242-09173F13E4C5 n4:271B5406-363D-11E5-9242-09173F13E4C5 n4:271B5407-363D-11E5-9242-09173F13E4C5 n4:271B53ED-363D-11E5-9242-09173F13E4C5 n4:271B53EE-363D-11E5-9242-09173F13E4C5 n4:271B53EC-363D-11E5-9242-09173F13E4C5 n4:271B53F5-363D-11E5-9242-09173F13E4C5 n4:271B53F6-363D-11E5-9242-09173F13E4C5 n4:271B53F3-363D-11E5-9242-09173F13E4C5 n4:271B53F4-363D-11E5-9242-09173F13E4C5
n3:patent
n24:6132758
n3:synonym
Claritin Loratadina Loratadinum
n3:toxicity
somnolence, tachycardia, and headache LD<sub>50</sub>=mg/kg (orally in rat)
n10:hasAHFSCode
n11:04-08-00 n11:24-32-04
n3:foodInteraction
Take on empty stomach: 1 hour before or 2 hours after meals.
n3:mixture
n29:271B53E9-363D-11E5-9242-09173F13E4C5 n29:271B53EA-363D-11E5-9242-09173F13E4C5 n29:271B53E7-363D-11E5-9242-09173F13E4C5 n29:271B53E8-363D-11E5-9242-09173F13E4C5 n29:271B53EB-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
97-99%
n3:synthesisReference
Alberto Stampa, Pelayo Camps, Gloria Rodriguez, Jordi Bosch, Maria del Carmen Onrubia, "Process for the preparation of loratadine." U.S. Patent US6084100, issued July 04, 2000.
n26:hasConcept
n27:M0026329
foaf:page
n22:loratadine.html n28:lorat.htm
n3:IUPAC-Name
n7:271B5448-363D-11E5-9242-09173F13E4C5
n3:InChI
n7:271B544E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n7:271B544D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B544A-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n7:271B544B-363D-11E5-9242-09173F13E4C5
n3:SMILES
n7:271B544C-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n7:271B5446-363D-11E5-9242-09173F13E4C5 n7:271B545D-363D-11E5-9242-09173F13E4C5
n3:logP
n7:271B5444-363D-11E5-9242-09173F13E4C5 n7:271B5447-363D-11E5-9242-09173F13E4C5 n7:271B545F-363D-11E5-9242-09173F13E4C5
n3:logS
n7:271B5445-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n31:R06AX13
n3:H-Bond-Acceptor-Count
n7:271B5454-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n7:271B5455-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n7:271B544F-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n7:271B5450-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n7:271B5452-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n7:271B5451-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n7:271B5453-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed following oral administration (40% bioavailability)
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
79794-75-5
n3:category
n3:containedIn
n5:271B5431-363D-11E5-9242-09173F13E4C5 n5:271B5432-363D-11E5-9242-09173F13E4C5 n5:271B542F-363D-11E5-9242-09173F13E4C5 n5:271B5430-363D-11E5-9242-09173F13E4C5 n5:271B542D-363D-11E5-9242-09173F13E4C5 n5:271B542E-363D-11E5-9242-09173F13E4C5 n5:271B5439-363D-11E5-9242-09173F13E4C5 n5:271B5437-363D-11E5-9242-09173F13E4C5 n5:271B5438-363D-11E5-9242-09173F13E4C5 n5:271B5435-363D-11E5-9242-09173F13E4C5 n5:271B5436-363D-11E5-9242-09173F13E4C5 n5:271B541B-363D-11E5-9242-09173F13E4C5 n5:271B541C-363D-11E5-9242-09173F13E4C5 n5:271B5419-363D-11E5-9242-09173F13E4C5 n5:271B541A-363D-11E5-9242-09173F13E4C5 n5:271B5418-363D-11E5-9242-09173F13E4C5 n5:271B5423-363D-11E5-9242-09173F13E4C5 n5:271B5424-363D-11E5-9242-09173F13E4C5 n5:271B5421-363D-11E5-9242-09173F13E4C5 n5:271B5422-363D-11E5-9242-09173F13E4C5 n5:271B541F-363D-11E5-9242-09173F13E4C5 n5:271B5420-363D-11E5-9242-09173F13E4C5 n5:271B541D-363D-11E5-9242-09173F13E4C5 n5:271B541E-363D-11E5-9242-09173F13E4C5 n5:271B542B-363D-11E5-9242-09173F13E4C5 n5:271B542C-363D-11E5-9242-09173F13E4C5 n5:271B5429-363D-11E5-9242-09173F13E4C5 n5:271B542A-363D-11E5-9242-09173F13E4C5 n5:271B5427-363D-11E5-9242-09173F13E4C5 n5:271B5428-363D-11E5-9242-09173F13E4C5 n5:271B5425-363D-11E5-9242-09173F13E4C5 n5:271B5426-363D-11E5-9242-09173F13E4C5 n5:271B5433-363D-11E5-9242-09173F13E4C5 n5:271B5434-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n7:271B5459-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n7:271B545B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n7:271B545C-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n7:271B545E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n7:271B5458-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n7:271B5457-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n7:271B545A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n7:271B5449-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n7:271B5456-363D-11E5-9242-09173F13E4C5